- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00034528
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
Allogeneic Stem Cell Transplantation Following Nonmyeloablative Chemotherapy in Patients With Hemoglobinopathies
연구 개요
상태
상세 설명
Hemoglobinopathies, such as sickle cell disease and thalassemia major, are genetic diseases associated with significant morbidity and premature death. Allogeneic bone marrow transplantation (BMT) is the only potential cure for severe hemoglobinopathies. Typical regimens have used high doses of chemotherapy or chemo-radiotherapy to ablate recipient hematopoiesis and to prevent graft rejection. The widespread use of this treatment has been limited by toxicity, risk of end-organ damage, and donor availability. This study will use a nonmyeloablative regimen of fludarabine and busulfan to attempt to generate consistent engraftment with donor hematopoietic stem cells in patients with severe hemoglobinopathy.
G-CSF mobilization of the donor's peripheral blood white blood cells will precede donor apheresis. A nonmyeloablative conditioning regimen of fludarabine and busulfan will be administered to patients prior to allogeneic peripheral blood stem cell infusions. FK506 and prednisone will be administered for graft versus host disease (GVHD) prophylaxis. Patients will be evaluated for engraftment, donor: host hematopoietic chimerism, toxicity, and hemoglobinopathy.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02115
- Dana-Farber Cancer Institute/Harvard Cancer Center, Brigham and Women's Hospital and Massachusetts General Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion criteria:
All patients must:
- Have related donors who are identical at 6 human leukocyte antigens (HLA) loci (A, B and DR) by molecular typing
- Have a performance status from 0-2
- Give written informed consent
Patients with sickle cell disease should have 1 or more of the following:
- Acute chest syndrome requiring recurrent hospitalization or exchange transfusion
- Nonhemorrhagic stroke or central nervous system event lasting longer than 24 hours
- Recurrent vaso-occlusive pain (2 episodes or more per year) or recurrent priapism
- Sickle nephropathy (moderate or severe proteinuria or a glomerular filtration rate 30-50 percent of normal predicted value)
- Bilateral proliferative retinopathy and major visual impairment in at least 1 eye
- Osteonecrosis of multiple joints
Patients with thalassemia should have 1 or more of the following:
- Transfusion dependence, defined as a transfusion requirement of greater than or equal to 6 units of packed red blood cells over the past 12 months
- Iron overload, defined as serum ferritin greater than 500 mcg/L in the absence of infection or biopsy-proven iron overload
- Presence of 2 or more alloantibodies against red cell antigens
Exclusion criteria:
- Pregnancy
- Acute hepatitis (transaminases greater than 3 times the normal value)
- Cardiac ejection fraction less than 30 percent
- Severe renal impairment (glomerular filtration rate less than 30 percent of predicted normal value)
- Severe residual functional neurologic impairment (other than hemiplegia alone)
- Seropositivity for the human immunodeficiency virus (HIV)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Allogeneic stem cell transplantation
Participants will receive a nonmyeloablative conditioning regimen of fludarabine and busulfan prior to allogeneic peripheral blood stem cell (CD34+) infusions.
FK506 and prednisone will be administered for graft versus host disease (GVHD) prophylaxis.
|
0.8 mg/kg/d administered as a single intravenous infusion over 3 hours for 4 days.
All infusions are anticipated to be given in the outpatient clinic.
다른 이름들:
30 mg/m^2/d administered as a bolus infusion over 30 minutes for 4 days.
All infusions are anticipated to be given in the outpatient clinic.
다른 이름들:
0.15 mg/kg taken orally daily for 12 to 14 weeks
다른 이름들:
0.5 mg/kg taken orally four times daily on Day 7 and increase to 1 mg/kg taken orally four times daily on Day 14. Participants will continue regimen until Day 30 before a 20-25% taper per week.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Evidence of engraftment of donor hematopoietic cells following administration of low doses of busulfan and fludarabine
기간: Throughout study
|
Throughout study
|
2차 결과 측정
결과 측정 |
기간 |
---|---|
Solid organ toxicity related to the conditioning regimen
기간: Throughout study
|
Throughout study
|
Incidence of grade II, III, or IV acute graft versus host disease (GVHD)
기간: Throughout study
|
Throughout study
|
Level of disease response
기간: Throughout study
|
Throughout study
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Catherine J. Wu, MD, Dana-Farber Cancer Institute
간행물 및 유용한 링크
일반 간행물
- Walters MC, Storb R, Patience M, Leisenring W, Taylor T, Sanders JE, Buchanan GE, Rogers ZR, Dinndorf P, Davies SC, Roberts IA, Dickerhoff R, Yeager AM, Hsu L, Kurtzberg J, Ohene-Frempong K, Bunin N, Bernaudin F, Wong WY, Scott JP, Margolis D, Vichinsky E, Wall DA, Wayne AS, Pegelow C, Redding-Lallinger R, Wiley J, Klemperer M, Mentzer WC, Smith FO, Sullivan KM. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood. 2000 Mar 15;95(6):1918-24.
- Gomez-Almaguer D, Ruiz-Arguelles GJ, Ruiz-Arguelles A, Gonzalez-Llano O, Cantu OE, Hernandez NE. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases. Bone Marrow Transplant. 2000 Jan;25(2):131-3. doi: 10.1038/sj.bmt.1702100.
- Krishnamurti L, Blazar BR, Wagner JE. Bone marrow transplantation without myeloablation for sickle cell disease. N Engl J Med. 2001 Jan 4;344(1):68. doi: 10.1056/NEJM200101043440119. No abstract available.
- Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS, Champlin RE, Vaughan WP. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant. 2000;6(5A):548-54. doi: 10.1016/s1083-8791(00)70064-4.
- Wu CJ, Krishnamurti L, Kutok JL, Biernacki M, Rogers S, Zhang W, Antin JH, Ritz J. Evidence for ineffective erythropoiesis in severe sickle cell disease. Blood. 2005 Nov 15;106(10):3639-45. doi: 10.1182/blood-2005-04-1376. Epub 2005 Aug 9.
- Wu CJ, Gladwin M, Tisdale J, Hsieh M, Law T, Biernacki M, Rogers S, Wang X, Walters M, Zahrieh D, Antin JH, Ritz J, Krishnamurti L. Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis. Br J Haematol. 2007 Nov;139(3):504-7. doi: 10.1111/j.1365-2141.2007.06803.x. No abstract available.
- Wu CJ, Hochberg EP, Rogers SA, Kutok JL, Biernacki M, Nascimento AF, Marks P, Bridges K, Ritz J. Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. Exp Hematol. 2003 Oct;31(10):924-33. doi: 10.1016/s0301-472x(03)00227-3.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- DAIT DF/HCC 01-098
- P01 A 129530
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
빈혈, 낫적혈구에 대한 임상 시험
-
Sandy SrinivasGlaxoSmithKline완전한방광암 | 방광(요로상피, 이행세포) 암 | 방광(Urothelial, Transitional Cell) 절제 가능한 암(방광절제술 전) | 방광(Urothelial, Transitional Cell) 암 표재성(비침습성) | 방광(Urothelial, Transitional Cell) 암 전이성 또는 절제 불가능미국
-
Stanford UniversityNational Institutes of Health (NIH)빼는방광암 | 피부암 | 방광(요로상피, 이행세포) 암 | 방광(Urothelial, Transitional Cell) 절제 가능한 암(방광절제술 전)미국
-
Millennium Pharmaceuticals, Inc.완전한GCB(Non-Germinal B-cell-like) 미만성 거대 B-세포 림프종(DLBCL)미국
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI); Genentech, Inc.모병미만성 거대 B세포 림프종 | 재발성 미만성 대형 B세포 림프종 | 난치성 미만성 대형 B세포 림프종 | 원발성 종격동(흉선) 대형 B세포 림프종 | 등급 3b 여포성 림프종 | 변형된 여포 림프를 Diff 대형 B-세포 림프종으로 | 변형된 마그 존 림프를 Diff Large B-Cell Lymphoma로미국
-
University of Alabama at Birmingham종료됨역형성 대세포 림프종 | 혈관면역모세포성 T세포 림프종 | 말초 T 세포 림프종 | 성인 T 세포 백혈병 | 성인 T 세포 림프종 | 상세불명의 말초 T 세포 림프종 | T/Null Cell 전신형 | 림프절/내장 질환을 동반한 피부 T세포 림프종미국
Busulfan에 대한 임상 시험
-
Shanghai Public Health Clinical CenterR&D Kanglin Biotech알려지지 않은
-
Institut Paoli-Calmettes알려지지 않은백혈병, 골수성, 급성 | 백혈병, 림프구성, 급성프랑스
-
The First Affiliated Hospital of Soochow University모병
-
University Hospital, Basel, SwitzerlandUniversity Hospital, Geneva; University Hospital, Zürich완전한
-
Hackensack Meridian Health종료됨골수증식성 장애 | 골수 형성 이상 증후군 | 급성 골수성 백혈병 | 만성 골수성 백혈병 | 골수성 악성종양미국
-
Massachusetts General HospitalDana-Farber Cancer Institute완전한호지킨 림프종 | 만성림프구성백혈병 | 저등급 림프종 | 미만성, 대형 B세포, 림프종 | T 세포 림프종 | 외투세포 림프종 | 림프종, 소림프구성미국
-
Chinese PLA General Hospital309th Hospital of Chinese People's Liberation Army; Beijing Naval General Hospital; Space...알려지지 않은